RT Journal Article SR Electronic T1 HPV16-L1-specific Antibody Response Is Associated with Clinical Remission of High-risk HPV-positive Early Dysplastic Lesions JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5127 OP 5132 VO 34 IS 9 A1 GRIT MEHLHORN A1 SIMONE K. HAUTMANN A1 MARTIN C. KOCH A1 JOHANNA D. STREHL A1 ARNDT HARTMANN A1 RALF HILFRICH A1 MATTHIAS W. BECKMANN A1 HENRIK GRIESSER YR 2014 UL http://ar.iiarjournals.org/content/34/9/5127.abstract AB Background/Aim: The present study was aimed at clarifying if use of a rapid human papillomavirus type 16 L1-specific antibody test could be used to improve clinical management of high-risk HPV-positive low-grade squamous intraepithelial lesion (LSIL)/high-grade squamous intraepithelial lesion (HSIL). Patients and Methods: The study was nested within a prospective study of 801 patients with early dysplastic high-risk HPV-positive lesions to examine the prognostic significance of HPV-L1 protein detection. Serum samples of 87 patients were tested with a rapid HPV16-L1-specific antibody test. The results were correlated with the clinical outcome during 66 months of follow-up. Results: A combined analysis of the 22 antibody-positive women showed that 17 were also L1 protein-positive, and 5 were L1 capsid protein-negative. An HPV-specific immune competence strongly correlates with clinical remission of low-grade squamous intraepithelial lesion (76.6%). For L1 antigen and HPV16-L1 antibody double-positive women, the risk of progression to cervical intraepithelial neoplasia grade 3 was low (5.8%). Conclusion: The rapid anti-HPV16-L1 test could be a promising tool to improve risk assessment and appropriate clinical management of high-risk HPV-positive early dysplastic lesions.